Search
Now showing items 1-10 of 16
Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population
(
Nature Research
, 2021 , Article)
Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 "ever" (past or current) infection in a population-based sample in a high exposure setting. PCR and serological ...
Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February-18 April 2020
(
BMJ Publishing Group
, 2020 , Article)
© Authors 2020 Objective To define the epidemiological curve of COVID-19 in Qatar and determine factors associated with severe or critical illness. Design Case series of first 5685 COVID-19 cases in Qatar. Setting and ...
Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months
(
Elsevier
, 2021 , Article)
We document two cases of viremic and prolonged active infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) where the viral genome was conserved for two months, but infection was with little or ...
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections.
(
Springer
, 2022 , Article)
SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior infection have been observed globally, but the transmission potential of these infections is unknown. The RT-qPCR cycle threshold ...
Severity, criticality, and fatality of the SARS-CoV-2 Beta variant
(
Oxford Academic
, 2021 , Article)
Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to ...
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
(
Nature Researc
, 2021 , Article)
With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines ...
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.
(
American Medical Association
, 2021 , Article)
The effect of prior SARS-CoV-2 infection on vaccine protection remains poorly understood. To assess protection from SARS-CoV-2 breakthrough infection after mRNA vaccination among persons with vs without prior SARS-CoV-2 ...
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
(
Oxford University Press
, 2021 , Article)
Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether delaying administration of the second vaccine dose to vaccinate the largest number of ...
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
(
Elsevier
, 2021 , Article)
Background
Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive ...
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar.
(
Oxford University Press
, 2021 , Article)
Qatar experienced a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic that disproportionately affected the craft and manual worker (CMW) population, who comprise 60% of the total population. This study ...